Comparison of bleomycin polidocanol foam versus absolute ethanol for sclerotherapy of venous malformations

IF 3.1 2区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-03-01 Epub Date: 2025-11-06 DOI:10.1016/j.jvsv.2025.102352

Jiayi Lai MD, Zian Xu MD, Hui Chen MD, PhD, Li Hu MD, PhD, Xiaoxi Lin MD, PhD, Xi Yang MD

{"title":"Comparison of bleomycin polidocanol foam versus absolute ethanol for sclerotherapy of venous malformations","authors":"Jiayi Lai MD, Zian Xu MD, Hui Chen MD, PhD, Li Hu MD, PhD, Xiaoxi Lin MD, PhD, Xi Yang MD","doi":"10.1016/j.jvsv.2025.102352","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The purpose of this study was to compare the efficacy and safety between two sclerosants for venous malformations (VMs), bleomycin polidocanol foam (BPF) and absolute ethanol (AE), and provide more clinical evidence for the application of BPF for VMs.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of 104 patients with VMs who had been treated with BPF and AE sclerotherapy. Patients were followed-up after treatment to assess clinical efficacy and complications. Clinical efficacy was independently evaluated by three experts based on pre- and post-treatment photos and magnetic resonance images. Complications were categorized according to the Society of Interventional Radiology Adverse Event Classification System.</div></div><div><h3>Results</h3><div>A total of 104 patients with VM were enrolled in this study, of which 53 (51%) received BPF sclerotherapy, and 51 (49%) received AE sclerotherapy. Most of the patients had head and neck VMs (n = 64; 62%), and the most common symptom was disfigurement. The number of sessions in the BPF group was significantly lower than in the AE group (1.5 vs 2.2; <em>P</em> < .05). The median treatment efficacy score was 3.0 for the BPF group and 2.7 for the AE group, with no significant difference between two groups. The median follow-up was 45 months for the BPF group and 33 months for the AE group, with no significant difference between two groups. Complications occurred in 11 patients in the BPF group and in 15 patients in the AE group, but there was no significant difference between the two groups. Mild adverse events occurred in 10 of 53 patients (19%) in the BPF group and 10 of 51 (20%) in the AE group. Moderate adverse events occurred in one patient (2%) in the BPF group and three patients (6%) in the AE group. Two patients (4%) in the AE group had nerve injury, evaluated as severe adverse events, whereas no patients in the BPF group did.</div></div><div><h3>Conclusions</h3><div>BPF has comparable treatment efficacy to AE in sclerotherapy for VMs. BPF showed a trend toward a lower rate of severe adverse events, although this difference was not statistically significant in our cohort. It could be an optimal sclerosant to treat VMs.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102352"},"PeriodicalIF":3.1000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of vascular surgery. Venous and lymphatic disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213333X25001878","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The purpose of this study was to compare the efficacy and safety between two sclerosants for venous malformations (VMs), bleomycin polidocanol foam (BPF) and absolute ethanol (AE), and provide more clinical evidence for the application of BPF for VMs.

Methods

We conducted a retrospective study of 104 patients with VMs who had been treated with BPF and AE sclerotherapy. Patients were followed-up after treatment to assess clinical efficacy and complications. Clinical efficacy was independently evaluated by three experts based on pre- and post-treatment photos and magnetic resonance images. Complications were categorized according to the Society of Interventional Radiology Adverse Event Classification System.

Results

A total of 104 patients with VM were enrolled in this study, of which 53 (51%) received BPF sclerotherapy, and 51 (49%) received AE sclerotherapy. Most of the patients had head and neck VMs (n = 64; 62%), and the most common symptom was disfigurement. The number of sessions in the BPF group was significantly lower than in the AE group (1.5 vs 2.2; P < .05). The median treatment efficacy score was 3.0 for the BPF group and 2.7 for the AE group, with no significant difference between two groups. The median follow-up was 45 months for the BPF group and 33 months for the AE group, with no significant difference between two groups. Complications occurred in 11 patients in the BPF group and in 15 patients in the AE group, but there was no significant difference between the two groups. Mild adverse events occurred in 10 of 53 patients (19%) in the BPF group and 10 of 51 (20%) in the AE group. Moderate adverse events occurred in one patient (2%) in the BPF group and three patients (6%) in the AE group. Two patients (4%) in the AE group had nerve injury, evaluated as severe adverse events, whereas no patients in the BPF group did.

Conclusions

BPF has comparable treatment efficacy to AE in sclerotherapy for VMs. BPF showed a trend toward a lower rate of severe adverse events, although this difference was not statistically significant in our cohort. It could be an optimal sclerosant to treat VMs.

查看原文本刊更多论文

博来霉素聚多醇泡沫与无水乙醇硬化治疗静脉畸形的比较。

目的：比较博来霉素聚多醇泡沫（BPF）和无水乙醇（AE）两种硬化剂治疗静脉畸形（vm）的疗效和安全性，为BPF在vm中的应用提供更多临床依据。方法：我们对104例接受BPF和AE硬化治疗的vm患者进行了回顾性研究。治疗后随访患者，评估临床疗效及并发症。临床疗效由三位专家根据治疗前后照片和磁共振图像独立评估。并发症按照介入放射学会（SIR）不良事件分类系统进行分类。结果：104例VM患者入组，其中53例（51%）接受BPF硬化治疗，51例（49%）接受AE硬化治疗。大多数患者有头颈部vm (n=64, 62%)，最常见的症状是毁容。BPF组的治疗次数明显低于AE组（1.5 vs 2.2）。结论：BPF在vm硬化治疗中的疗效与无水乙醇相当。BPF显示出严重不良事件发生率较低的趋势，尽管这种差异在我们的队列中没有统计学意义。它可能是治疗vm的最佳硬化剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of vascular surgery. Venous and lymphatic disorders SURGERYPERIPHERAL VASCULAR DISEASE&n-PERIPHERAL VASCULAR DISEASE

CiteScore

6.30

自引率

18.80%

发文量

328

审稿时长

71 days

期刊介绍： Journal of Vascular Surgery: Venous and Lymphatic Disorders is one of a series of specialist journals launched by the Journal of Vascular Surgery. It aims to be the premier international Journal of medical, endovascular and surgical management of venous and lymphatic disorders. It publishes high quality clinical, research, case reports, techniques, and practice manuscripts related to all aspects of venous and lymphatic disorders, including malformations and wound care, with an emphasis on the practicing clinician. The journal seeks to provide novel and timely information to vascular surgeons, interventionalists, phlebologists, wound care specialists, and allied health professionals who treat patients presenting with vascular and lymphatic disorders. As the official publication of The Society for Vascular Surgery and the American Venous Forum, the Journal will publish, after peer review, selected papers presented at the annual meeting of these organizations and affiliated vascular societies, as well as original articles from members and non-members.